The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The rapid rise of obesity and type 2 diabetes poses a global threat to healthcare and is a major cause of mortality and morbidity. Bariatric surgery has revolutionised the treatment of both these conditions but is invasive and associated with an increased risk of complications. The EndoBarrier is a device placed endoscopically in the duodenum, which is designed to mimic the effects of gastric bypass surgery with the aim of inducing weight loss and improving glycaemic control. This review outlines the current clinical evidence of the device, its efficacy, potential mechanisms of action, and utility in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880 · cited 1×
“Numerous studies have shown an increase in certain bacterial species, which include Gammaproteobacteria following RYGB [32, 33].”
BackgroundDifferential Adaptation of Human Gut Microbiota to Bariatric Surgery–Induced Weight Loss
Furet, J.-P., Kong, L.-C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.-L., Mariat, D., Corthier, G., Doré, J., Henegar, C., et al. (2010) · Diabetes · doi:10.2337/db10-0253 · Cited by 1,173 · cited 1×
“A reduction in the proportion of Bacteroidetes has been observed in obese individuals when compared with lean individuals, and these species of bacteria appear to increase postbariatric surgery [28, 29].”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“In fact, it is estimated that the incretin effect accounts for as much as 50–70% of insulin secretion in response to an oral glucose load [13].”
BackgroundLaferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · cited 1×
“Following RYGB, the role of GIP is more unclear as there are conflicting reports of GIP levels with some studies showing an increase whilst others show decreased levels or no change at all [15, 18, 19].”
BackgroundPatti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591 · cited 1×
“to increased levels of plasma BAs postsurgery compared with at baseline [25].”
BackgroundKong, L.-C., Tap, J., Aron-Wisnewsky, J., Pelloux, V., Basdevant, A., Bouillot, J.-L., Zucker, J.-D., Doré, J., & Clément, K. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.058743 · Cited by 416 · cited 1×
“Numerous studies have shown an increase in certain bacterial species, which include Gammaproteobacteria following RYGB [32, 33].”
BackgroundJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313 · cited 2×
“Following RYGB, the role of GIP is more unclear as there are conflicting reports of GIP levels with some studies showing an increase whilst others show decreased levels or no change at all [15, 18, 19].”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Riedel, N., Laubner, K., Lautenbach, A., Schön, G., Schlensak, M., Stengel, R., Eberl, T., Dederichs, F., Aberle, J., & Seufert, J. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.02.029 · Cited by 15 · cited 1×
“The German DJBL registry reported 1 case in 66 patients who had received the EndoBarrier for one year having previously reported 4 cases in a 235 patient registry [36].”
Method
Cited by
Karlas, T., Petroff, D., Feisthammel, J., Beer, S., Blüher, M., Schütz, T., Lichtinghagen, R., Hoffmeister, A., & Wiegand, J. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06150-5 · Cited by 26
Updates in endoscopic bariatric and metabolic therapies.
Qureshi, H., Saeed, N., & Jovani, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031126 · Cited by 21
“The consequence is that there is a decrease in the production of anti-incretins, which leads to increased incretin production, increased bile acid production as possibly favorable modifications of the gut microbiota [54,55].”
BackgroundRoehlen, N., Laubner, K., Nicolaus, L., Schwacha, H., Bettinger, D., Krebs, A., Thimme, R., & Seufert, J. (2022) · Nutrition · doi:10.1016/j.nut.2022.111806 · Cited by 17
Metadata
- Authors
- Ruban, A., Ashrafian, H., & Teare, J. P.
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2018-07-26
- Volume
- 2018
- Pages
- 1-9
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- OpenAlex
- W2884311996
- Cited by
- 76
- References
- 10
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss. https://app.cochat.ai/papers/10.1155/2018/7823182
- The paper
- Ruban, A., Ashrafian, H., & Teare, J. P. (2018). The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss. Gastroenterology Research and Practice. https://doi.org/10.1155/2018/7823182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.